Sultanalieva R B, Abylova N K, Zhunusova B Z
Diabetic and Endocrinological Association of Kyrgyzstan; Kyrgyz State Medical Institute of Retraining and Advanced Training.
Diabetic and Endocrinological Association of Kyrgyzstan; Kyrgyz State Medical Institute of Retraining and Advanced Training; International High School of Medicine.
Probl Endokrinol (Mosk). 2025 May 20;71(2):55-65. doi: 10.14341/probl13502.
The State Register of Diabetes Patients (SRDP) was first introduced throughout the Kyrgyz Republic in 2015 and has become one of the priority areas in the endocrinological service of the republic. The creation of a national registry was a significant step towards optimizing care for people with diabetes mellitus (DM). Currently, the register in the Kyrgyz Republic does not work online software, so all information about diabetes is assessed statically, representing a one-time snapshot for the end of the calendar year.
To study epidemiological aspects (prevalence,incidence mortality), as well as the frequency of complications of diabetes mellitus in Kyrgyzstan and the largest populated city in the country - Bishkek.
The object of the study is the database of the DM register for the Kyrgyz Republic and the city of Bishkek (data over time from 2016-2023).
The total number of patients with diabetes registered in the dispensary in Kyrgyzstan as of 01/01/2024, according to the SRDP, was 85,142 people, which amounted to 1.2% of the total population of the republic. In Kyrgyzstan, according to the register, among patients with T1DM, the proportion of males was 52.4%, and females - 47.6%, and in the group of patients with T2DM, females predominated (59.9%). The prevalence of diabetes in the Kyrgyz Republic over the analyzed 8-year period (2016-2023) among patients with type 1 diabetes increased from 37/100ths of the population to 49.8/100ths of the population (1.35 times), and with T2DM - from 847.6/100ths population to 1159.0/100ths population (1.37 times). The dynamics of the annual incidence of T1DM in the Kyrgyz Republic averages 3.6 per 100ths population, and T2DM increased from 2016 to 2019, increasing by 27.6%, from 85 to 108.5/100ths population and decreased to 94/100 thousand population in 2023. The most common complications among patients with type 1 diabetes in the republic remain: neuropathy, retinopathy, nephropathy, and for type 2 diabetes - neuropathy, hypertension, retinopathy. According to the register, during the analyzed period there was a stabilization and/or decrease in the frequency of most diabetic complications, with the exception of stroke, diabetic foot (DF), and acute micardial infarction (AMI).
The SRDP in Kyrgyzstan, over 8 years of operation in static mode, has allowed for clinical and epidemiological monitoring, ensuring observation of patients from the moment of inclusion in the registry and providing data on the prevalence, incidence and complications of diabetes. However, the registry's operation is hampered by the lack of access to the Internet and computers in a number of regions, as well as the timeliness of data entry. The transfer of the SRDP to an online format is necessary for effective monitoring and control of key disease indicators in real time.
《糖尿病患者国家登记册》（SRDP）于2015年首次在吉尔吉斯共和国全境推行，已成为该国内分泌服务的重点领域之一。创建国家登记册是优化糖尿病患者护理工作的重要一步。目前，吉尔吉斯共和国的登记册没有在线软件，因此所有糖尿病信息都是静态评估的，代表着日历年末的一次性快照。
研究吉尔吉斯斯坦以及该国人口最多的城市——比什凯克的糖尿病流行病学方面（患病率、发病率、死亡率）以及糖尿病并发症的发生频率。
研究对象是吉尔吉斯共和国和比什凯克市糖尿病登记册的数据库（2016 - 2023年期间的数据）。
根据SRDP，截至2024年1月1日，吉尔吉斯斯坦诊疗所登记的糖尿病患者总数为85142人，占共和国总人口的1.2%。在吉尔吉斯斯坦，根据登记册，1型糖尿病患者中男性占比52.4%，女性占47.6%，而在2型糖尿病患者组中，女性占主导（59.9%）。在分析的8年期间（2016 - 2023年），吉尔吉斯共和国1型糖尿病患者的患病率从每10000人中37人增至49.8人（增长了1.35倍），2型糖尿病患者的患病率从每10000人中847.6人增至1159.0人（增长了1.37倍）。吉尔吉斯共和国1型糖尿病的年发病率动态平均为每10000人3.6例，2型糖尿病从2016年到2019年有所增加，增长了27.6%，从每10000人85例增至108.5例，2023年降至94/10万人口。该共和国1型糖尿病患者中最常见的并发症仍然是：神经病变、视网膜病变、肾病，2型糖尿病患者的并发症是：神经病变、高血压、视网膜病变。根据登记册，在分析期间，除中风、糖尿病足（DF）和急性心肌梗死（AMI）外，大多数糖尿病并发症的发生频率趋于稳定和/或下降。
吉尔吉斯斯坦的SRDP在静态模式下运行8年，实现了临床和流行病学监测，确保从患者纳入登记册之时起对其进行观察，并提供有关糖尿病患病率、发病率和并发症的数据。然而，登记册的运行受到一些地区互联网和计算机接入不足以及数据录入及时性的阻碍。将SRDP转换为在线格式对于实时有效监测和控制关键疾病指标是必要的。
